Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) now have 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $1,189.00 and $720.00 calculating the average target price we see $1,048.72. Given that the stocks previous close was at $901.19 this indicates there is a potential upside of 16.4%. Also worth taking note is the 50 day moving average now sits at $953.63 and the 200 day moving average is $858.32. The company has a market capitalization of 98.13B. The stock price for the company is currently $893.99 USD
The potential market cap would be $114,189,939,987 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 25.72, revenue per share of $122.94 and a 8.49% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
